Yahoo Insider Transactions
great entry - thanks all
Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
By Adam Feuerstein
05/13/15 - 05:00 PM EDT
The research abstracts went live on ASCO's website at 5 p.m. EDT today, which means health care investors are now busy downloading and reading to find investable, stock-moving nuggets of clinical data.
Luckily, I had early access to the ASCO abstracts under an embargo. What follows is a list and summary of abstracts likely to be of greatest interest to biotech investors.
2 year prolonged survival rate on a cancer biotech is huge on Wall Street
Sentiment: Strong Buy
The Fly On The Wall
Breaking News Feed
H.C. Wainwright Initiates Buy on Celladon ( CLDN ) - Cites Impressive Trial Results For Heart Failure Therapy
Clinical trial results are impressive—demonstrating statistically significantly improved outcomes. MYDICAR has been granted Breakthrough Therapy Designation,We see MYDICAR as a transformational approach to treating systolic heart failure."
top line phase III.. nice
make money -
The 5 Winners and Losers From ASCO Presentations
By Chris Lange
May 18, 2015
Winner ( ONTY )
Wall Street Journal
Fitbit Isn’t Too Stretched
Fitbit’s valuation leaves the stock some room to run, even after scoring a nice IPO pop.
By Dan Gallagher
June 1823 2015
The company, on July 01, 2015, reported that it has appointed Timothy Callahan and Richard Daly as new independent directors to its board. Both Mr. Callahan and Mr. Daly have direct experience in primary care and gastrointestinal markets and have led large organizational change and successful business growth, in a variety of areas, including all aspects of commercial, acquisitions, partnerships and product launches.
Mr. Callahan is a global life sciences business leader with over 21 years of experience in pharmaceutical and biologic commercialization, most recently with the Actavis organization.